Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody

IMAB362/Zolbetuximab, a first-in-class IgG1 antibody directed against the cancer-associated gastric-lineage marker CLDN18.2, has recently been reported to have met its primary endpoint in two phase 3 trials as a first-line treatment in combination with standard of care chemotherapy in CLDN18.2-posit...

Descripción completa

Detalles Bibliográficos
Autores principales: Bähr-Mahmud, Hayat, Ellinghaus, Ursula, Stadler, Christiane R., Fischer, Leyla, Lindemann, Claudia, Chaturvedi, Anuhar, Diekmann, Jan, Wöll, Stefan, Biermann, Imke, Hebich, Bernhard, Scharf, Caroline, Siefke, Manuela, Roth, Alexandra S., Rao, Martin, Brettschneider, Kerstin, Ewen, Eva-Maria, Şahin, Uğur, Türeci, Özlem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583639/
https://www.ncbi.nlm.nih.gov/pubmed/37860278
http://dx.doi.org/10.1080/2162402X.2023.2255041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583639/
https://www.ncbi.nlm.nih.gov/pubmed/37860278
http://dx.doi.org/10.1080/2162402X.2023.2255041

Ejemplares similares